Stryker has announced that its first interventional oncology technology, the OptaBlate bone tumour ablation system, has received 510(k) clearance from the US Food and Drug Administration (FDA).
The addition of OptaBlate to Stryker’s Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures.
Anthony Brown, a vascular and interventional radiologist at Radiology Imaging Associates (Englewood, USA), said: “Stryker’s new bone tumour ablation system is a significant improvement on existing technology and builds on Stryker’s IVS portfolio. There is no more deserving patient population for our attention and intervention; OptaBlate will change lives.”
OptaBlate is designed to optimise all aspects of the procedure—from set-up to ablation. Featuring four probes and patented microinfusion technology, OptaBlate allows physicians to easily customise their procedure and reduce ablation time by three minutes, according to Stryker.
Greg Siller, vice president and general manager of Stryker’s IVS business, added: “Our commitment to our customers and understanding their needs has never been stronger. The collaboration has helped us to develop a more efficient bone tumour ablation system to address their unmet needs.
“OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning.”